Clostridium difficile Examined by Different Methods
By LabMedica International staff writers Posted on 30 Apr 2018 |
Image: A positive C. DIFF QUIK CHEK COMPLETE. The assay simultaneously tests for GDH and Toxins A & B providing actionable C. difficile results in less than 30 minutes (Photo courtesy of Alere).
The epidemiology of Clostridium difficile infection (CDI) has shifted in the last decade and is now affecting populations previously at low risk to include healthy adults, peripartum women and young children.
The point prevalence of Clostridium difficile stool shedding in hospitalized infants from two neonatal intensive care units (NICUs) was examined utilizing standard clinical testing compared with duplex polymerase chain reaction (PCR) to identify toxigenic and non-toxigenic C. difficile strains.
Pediatric disease specialists at University of Nebraska Medical Center (Omaha, NE, USA) included all infants from the two NICUs affiliated with a single academic medical center were eligible for inclusion in the point prevalence survey. Stool collection was blinded to patient characteristics and occurred during a one-week period at each NICU and repeated with a second weeklong collection six months later to increase sample size.
Stools were tested for C. difficile using enzyme immunoassay (EIA) with samples testing +/+ or +/− subsequently evaluated by Loop-Mediated Isothermal Amplification. Cytotoxicity assays were performed on all samples positive for C. difficile by any modality (Clostridium difficile Toxin/Antitoxin kit. A rapid thermocycler was used to specifically amplify a conserved region of both toxigenic and non-toxigenic C. difficile tpi gene and a non-repeat region of the toxigenic C. difficile tcdB gene.
The scientists collected 84 stools from unique infants for evaluation. EIA results showed six+/+ (7.1%), seven +/− (8.3%), and 71 −/− [84.5%] samples. All six EIA +/+ were confirmed as toxigenic C. difficile by LAMP; 6/7 EIA +/− were negative by LAMP with one identified as invalid. Duplex PCR concurred with LAMP in all six stools positive for toxigenic C. difficile. PCR identified two EIA −/− stools positive for tpi, indicating shedding of non-toxigenic C. difficile. Cytotoxicity assay was positive in 4/6 duplex PCR positive samples and negative for all stools that were EIA +/− but negative by molecular testing.
The authors concluded that C. difficile blinded point prevalence in infants from two NICUs was 7.1% by molecular methods; and lower than expected based on historical incidence estimates. In house duplex PCR had excellent concordance with clinically available LAMP and EIA tests, and added detection of non-toxigenic C. difficile strain shedding. Evolving NICU care practices may be influencing the composition of infant gut microbiota and reducing the point prevalence of C. difficile shedding in NICU patient stools. The study was published on April 13, 2018, in the journal BMC Pediatrics.
Related Links:
University of Nebraska Medical Center
The point prevalence of Clostridium difficile stool shedding in hospitalized infants from two neonatal intensive care units (NICUs) was examined utilizing standard clinical testing compared with duplex polymerase chain reaction (PCR) to identify toxigenic and non-toxigenic C. difficile strains.
Pediatric disease specialists at University of Nebraska Medical Center (Omaha, NE, USA) included all infants from the two NICUs affiliated with a single academic medical center were eligible for inclusion in the point prevalence survey. Stool collection was blinded to patient characteristics and occurred during a one-week period at each NICU and repeated with a second weeklong collection six months later to increase sample size.
Stools were tested for C. difficile using enzyme immunoassay (EIA) with samples testing +/+ or +/− subsequently evaluated by Loop-Mediated Isothermal Amplification. Cytotoxicity assays were performed on all samples positive for C. difficile by any modality (Clostridium difficile Toxin/Antitoxin kit. A rapid thermocycler was used to specifically amplify a conserved region of both toxigenic and non-toxigenic C. difficile tpi gene and a non-repeat region of the toxigenic C. difficile tcdB gene.
The scientists collected 84 stools from unique infants for evaluation. EIA results showed six+/+ (7.1%), seven +/− (8.3%), and 71 −/− [84.5%] samples. All six EIA +/+ were confirmed as toxigenic C. difficile by LAMP; 6/7 EIA +/− were negative by LAMP with one identified as invalid. Duplex PCR concurred with LAMP in all six stools positive for toxigenic C. difficile. PCR identified two EIA −/− stools positive for tpi, indicating shedding of non-toxigenic C. difficile. Cytotoxicity assay was positive in 4/6 duplex PCR positive samples and negative for all stools that were EIA +/− but negative by molecular testing.
The authors concluded that C. difficile blinded point prevalence in infants from two NICUs was 7.1% by molecular methods; and lower than expected based on historical incidence estimates. In house duplex PCR had excellent concordance with clinically available LAMP and EIA tests, and added detection of non-toxigenic C. difficile strain shedding. Evolving NICU care practices may be influencing the composition of infant gut microbiota and reducing the point prevalence of C. difficile shedding in NICU patient stools. The study was published on April 13, 2018, in the journal BMC Pediatrics.
Related Links:
University of Nebraska Medical Center
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form